Analysts at Ladenburg Thalmann assumed coverage on shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) in a research note issued to investors on Wednesday. The firm set a “buy” rating on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on BLCM. Citigroup Inc. upgraded Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Tuesday, August 9th. Jefferies Group boosted their target price on Bellicum Pharmacueticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $31.00 target price (up from $25.00) on shares of Bellicum Pharmacueticals in a research report on Tuesday, August 9th. Zacks Investment Research downgraded Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 11th. Finally, Cantor Fitzgerald started coverage on Bellicum Pharmacueticals in a research report on Tuesday, November 1st. They set a “buy” rating and a $32.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $25.80.

Analyst Recommendations for Bellicum Pharmacueticals (NASDAQ:BLCM)

Bellicum Pharmacueticals (NASDAQ:BLCM) opened at 19.16 on Wednesday. The company’s 50-day moving average price is $18.69 and its 200-day moving average price is $16.37. The stock’s market capitalization is $519.33 million. Bellicum Pharmacueticals has a one year low of $7.24 and a one year high of $23.72.

Bellicum Pharmacueticals (NASDAQ:BLCM) last posted its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.03. The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.09 million. Bellicum Pharmacueticals had a negative return on equity of 49.65% and a negative net margin of 19,399.12%. The firm’s revenue for the quarter was up 90.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.51) earnings per share. Equities research analysts predict that Bellicum Pharmacueticals will post ($2.41) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was posted by Financial Market News and is the sole property of of Financial Market News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this story can be viewed at http://www.financial-market-news.com/bellicum-pharmacueticals-inc-blcm-now-covered-by-ladenburg-thalmann/1210266/.

In other news, CFO Alan A. Musso sold 29,300 shares of the business’s stock in a transaction on Monday, November 28th. The stock was sold at an average price of $19.51, for a total value of $571,643.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kevin M. Slawin sold 23,416 shares of the business’s stock in a transaction on Friday, September 23rd. The stock was sold at an average price of $20.12, for a total value of $471,129.92. Following the completion of the transaction, the insider now directly owns 95,464 shares of the company’s stock, valued at $1,920,735.68. The disclosure for this sale can be found here. 23.30% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System boosted its position in Bellicum Pharmacueticals by 147.3% in the second quarter. California State Teachers Retirement System now owns 43,946 shares of the biopharmaceutical company’s stock worth $570,000 after buying an additional 26,178 shares during the period. Bank of New York Mellon Corp boosted its position in Bellicum Pharmacueticals by 42.4% in the second quarter. Bank of New York Mellon Corp now owns 82,348 shares of the biopharmaceutical company’s stock worth $1,067,000 after buying an additional 24,538 shares during the period. First Eagle Investment Management LLC boosted its position in Bellicum Pharmacueticals by 45.2% in the second quarter. First Eagle Investment Management LLC now owns 854,055 shares of the biopharmaceutical company’s stock worth $11,069,000 after buying an additional 265,848 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Bellicum Pharmacueticals by 3.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 104,509 shares of the biopharmaceutical company’s stock worth $1,354,000 after buying an additional 3,888 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in Bellicum Pharmacueticals by 78.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 43,097 shares of the biopharmaceutical company’s stock worth $559,000 after buying an additional 18,936 shares during the period. 68.78% of the stock is owned by institutional investors.

About Bellicum Pharmacueticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

5 Day Chart for NASDAQ:BLCM

Receive News & Ratings for Bellicum Pharmacueticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmacueticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.